New pill for advanced prostate cancer shows early promise, but trial halted

NCT ID NCT03843918

Terminated Disease control Sponsor: Laekna Limited Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested an oral drug called LAE001 in 33 men with metastatic prostate cancer that had stopped responding to standard hormone therapy. The goal was to check safety and find the right dose, and to see if the drug could lower PSA levels. The trial was terminated early, so we have limited information on how well it works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: LAE001 (also known as CFG920), an oral drug
What this could lead to: If successful, this could point toward a new oral treatment option for metastatic prostate cancer that has stopped responding to hormone therapy.
What could go wrong: The trial was terminated early, so results are limited. It was a small, early-phase study (Phase I/II) focused on safety and dosing, not proof of effectiveness. The drug may not work or may cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER METASTATIC

Contacts and locations

Locations

Fudan Cancer Hospital

Shanghai, Shanghai Municipality, China
ZheJiang Cancer Hospital

Hangzhou, Zhejiang, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.